David Balli
About
David Balli is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, David Balli has authored 31 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Balli's work include Cancer Immunotherapy and Biomarkers (16 papers), FOXO transcription factor regulation (8 papers) and Cancer Genomics and Diagnostics (6 papers). David Balli is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), FOXO transcription factor regulation (8 papers) and Cancer Genomics and Diagnostics (6 papers). David Balli collaborates with scholars based in United States, Australia and France. David Balli's co-authors include Ben Z. Stanger, Vladimir V. Kalinichenko, Andrew J. Rech, Robert H. Vonderheide, Tanya V. Kalin, Ravikanth Maddipati, Robert J. Norgard, Jinyang Li, Emma E. Furth and Taiji Yamazoe and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.
In The Last Decade
David Balli
30 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David Balli United States | 16 | 826 | 764 | 464 | 360 | 264 | 31 | 1.6k | ||
| Janna Paulsson Sweden | 19 | 703 0.9× | 748 1.0× | 292 0.6× | 398 1.1× | 217 0.8× | 21 | 1.5k | ||
| Shinya Neri Japan | 19 | 1.1k 1.3× | 562 0.7× | 525 1.1× | 366 1.0× | 341 1.3× | 36 | 1.7k | ||
| Kathryn E. Ware United States | 16 | 548 0.7× | 870 1.1× | 513 1.1× | 399 1.1× | 171 0.6× | 27 | 1.5k | ||
| Pamela Villalobos United States | 18 | 621 0.8× | 598 0.8× | 350 0.8× | 329 0.9× | 161 0.6× | 27 | 1.3k | ||
| Joshua Armenia United States | 18 | 680 0.8× | 841 1.1× | 412 0.9× | 512 1.4× | 153 0.6× | 35 | 1.6k | ||
| Wassim Abida United States | 21 | 785 1.0× | 1.0k 1.3× | 945 2.0× | 583 1.6× | 138 0.5× | 93 | 1.9k | ||
| Sana Yokoi Japan | 21 | 498 0.6× | 870 1.1× | 378 0.8× | 297 0.8× | 122 0.5× | 43 | 1.4k | ||
| Min Hye Jang South Korea | 20 | 1.0k 1.2× | 610 0.8× | 279 0.6× | 473 1.3× | 303 1.1× | 42 | 1.7k | ||
| Hiroki Hashida Japan | 16 | 1.0k 1.3× | 768 1.0× | 181 0.4× | 359 1.0× | 404 1.5× | 58 | 1.8k | ||
| Jeonghee Cho South Korea | 18 | 518 0.6× | 685 0.9× | 422 0.9× | 343 1.0× | 175 0.7× | 31 | 1.2k |
Countries citing papers authored by David Balli
Since
Specialization
Citations
This map shows the geographic impact of David Balli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Balli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Balli more than expected).
Fields of papers citing papers by David Balli
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Balli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Balli. The network helps show where David Balli may publish in the future.
Co-authorship network of co-authors of David Balli
This figure shows the co-authorship network connecting the top 25 collaborators of David Balli. A scholar is included among the top collaborators of David Balli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Balli. David Balli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Awad, Mark M., Patrick M. Forde, Nicolas Girard, et al.. (2023). 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. Annals of Oncology. 34. S731–S731.
2.
Borghaei, Hossein, Kenneth J. O’Byrne, Luis Paz‐Ares, et al.. (2023). Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial. ESMO Open. 8(6). 102065–102065.
3.
Zalcman, Gérard, Robin Cornelissen, Laurent Greillier, et al.. (2022). LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Annals of Oncology. 33. S1438–S1439.
4.
Prasanna, Prateek, Germán Corredor, Cristian Barrera, et al.. (2022). Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. npj Precision Oncology. 6(1). 33–33.
5.
Peters, Solange, Arnaud Scherpereel, Robin Cornelissen, et al.. (2022). First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 33(5). 488–499.
6.
Long, Georgina V., Keyur Desai, Tania Tang, et al.. (2022). 788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). Annals of Oncology. 33. S904–S904.
7.
Ramalingam, Suresh S., David Balli, T-E. Ciuleanu, et al.. (2021). 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status. Annals of Oncology. 32. S1375–S1376.
8.
Peters, Solange, Arnaud Scherpereel, Robin Cornelissen, et al.. (2021). LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. Annals of Oncology. 32. S1341–S1342.
9.
Baden, Jonathan, Mark Sausen, Natallia Kalinava, et al.. (2021). Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.. Journal of Clinical Oncology. 39(15_suppl). 9010–9010.
10.
Paz‐Ares, Luis, T-E. Ciuleanu, Manuel Cobo, et al.. (2021). 98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA. Journal of Thoracic Oncology. 16(4). S750–S751.
11.
Balli, David, David Milewski, Tien Le, et al.. (2020). Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway. PLoS Genetics. 16(4). e1008692–e1008692.
12.
Bhagwat, Neha, Keely Dulmage, Charles H. Pletcher, et al.. (2018). An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Scientific Reports. 8(1). 5035–5035.
13.
Aiello, Nicole M., Ravikanth Maddipati, Robert J. Norgard, et al.. (2018). EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Developmental Cell. 45(6). 681–695.e4.
14.
Milewski, David, David Balli, Vladimir Ustiyan, et al.. (2017). FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. PLoS Genetics. 13(12). e1007097–e1007097.
15.
Balli, David, Andrew J. Rech, Ben Z. Stanger, & Robert H. Vonderheide. (2016). Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clinical Cancer Research. 23(12). 3129–3138.
16.
Cai, Yuqi, David Balli, Vladimir Ustiyan, et al.. (2013). Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis. Journal of Biological Chemistry. 288(31). 22527–22541.
17.
Balli, David, Vladimir Ustiyan, Yufang Zhang, et al.. (2013). Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition. The EMBO Journal. 32(2). 231–244.
18.
Balli, David, Yufang Zhang, Jonathan Snyder, Vladimir V. Kalinichenko, & Tanya V. Kalin. (2011). Endothelial Cell–Specific Deletion of Transcription Factor FoxM1 Increases Urethane-Induced Lung Carcinogenesis. Cancer Research. 71(1). 40–50.
19.
Balli, David, et al.. (2011). Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation. Oncogene. 31(34). 3875–3888.
20.
Wang, I‐Ching, Lucille N. Meliton, Xiaomeng Ren, et al.. (2009). Deletion of Forkhead Box M1 Transcription Factor from Respiratory Epithelial Cells Inhibits Pulmonary Tumorigenesis. PLoS ONE. 4(8). e6609–e6609.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Janna Paulsson Breakdown of academic impact, for papers by Shinya Neri Breakdown of academic impact, for papers by Kathryn E. Ware Breakdown of academic impact, for papers by Pamela Villalobos Breakdown of academic impact, for papers by Joshua Armenia Breakdown of academic impact, for papers by Wassim Abida Breakdown of academic impact, for papers by Sana Yokoi Breakdown of academic impact, for papers by Min Hye Jang Breakdown of academic impact, for papers by Hiroki Hashida Breakdown of academic impact, for papers by Jeonghee Cho